Drug intelligence / Profile preview

SIBI-C1

Development stage: Unknown
Lead developer: Siena Biotech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

SIBI-C1 is a humanized monoclonal antibody targeting CD47, a transmembrane protein that functions as a "don't eat me" signal by interacting with Signal Regulatory Protein Alpha (SIRPα) on macrophages. By inhibiting this interaction, SIBI-C1 promotes the phagocytosis of cancer cells by the innate immune system. Developed by Sibi Biotech (Beijing) Co., Ltd., the candidate is currently in early-phase clinical development for the treatment of advanced solid tumors and lymphomas. The drug is designed to overcome immune evasion mechanisms common in various malignancies.

Other names: anti-CD47 monoclonal antibodyanti-CD-47 monoclonal antibodyanti-CD 47 monoclonal antibody

Targets

SMO (Smoothened)

Beyond the preview

Go deeper on SIBI-C1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SIBI-C1.

Explore the full profile